Table 2.
Patient characteristics in [177Lu]Lu-DOTA-TATE treatment.
| Patient | Age | Gender | Primary location | Mutation | Previous treatments | Previous functional image | Metastases location | Cycles | Side effects | Biochemical response | Radiological response | Clinical response | Survival | PFS | Subsequent treatments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 38 | F | Abdominal PGL | SDHD | SSA a | MIBG d −DOPA e − FDG f + SRS g + | Lymph nodes, bone | 3 | No | - | PR | - | 81 months | 81 months | - |
| 2 | 20 | M | Left PHEO | NF1 | No | MIBG− FDG+ SRS++ | Bone, lung | 3 | GI | CR i | PR | SD asymptomatic | 80 months | 80 months | – |
| 3 | 46 | F | Abdominal PGL | Sporadic | Sunitinib, SSA, CVD b | MIBG+, FDG+, SRS++ | Liver, lymph nodes, bone | 1 | Hematologic grade 3 toxicity (adverse event) | PR j | SD k | PD | 5 months, exitus | 0 months | No |
| 4 | 50 | F | Abdominal PGL | SDHB | SSA, TMZ c , vertebral cementation. | FDG+, SRS+, gallium h + | Bone | 1 | No | – | SD | SD | 4 months, exitus | 4 months | No |
| 5 | 62 | M | Cervical PGL | SDHB | SSA | SRS+ | No (unresectable) | 4 | Acute cholecystitis after 2° cycle | PR | SD | SD asymptomatic | 42 months | 42 months | No |
| 6 | 51 | F | Left PHEO | Sporadic | SSA, bone RT. | FDG+, MIBG+/−, SRS+ | Lymph nodes, bone, lung | 4 | Hematologic grade 1 toxicity | CR | Pulmonary CR. SD in lymph nodes and bone | SD oligosymptomatic | 21 months | 21 months | No |
| 7 | 28 | M | Abdominal PGL | SDHB | CVD, vertebral cementation, SSA, pelvic RT, TMZ, 131I-MIBG. | SRS+ FDG++, MIBG+, Gallium++ | Lymph nodes, bone, lung | 4 | No | - | PR 10 months | SD 10 months | 12 months, exitus | 10 months | No |
| Afterwards PD l | Afterwards PD | ||||||||||||||
| 8 | 72 | M | Abdominal PGL | Sporadic | Bone RT, liver metastasectomy, SSA. | SRS+, MIBG+/−, Gallium++, FDG++ | Liver, lymph nodes, bone | 4 | Hematologic grade 1 toxicity | – | SD | SD | 17 months | 17 months | No |
| 9 | 45 | F | Right PHEO | Sporadic | SSA, abdominal implant resection, 131I-MIBG. | SRS+ MIBG+Gallium++ | Liver, lymph nodes, bone, pelvic implants | 4 | Hematologic grade 1 toxicity, GI | - | SD | SD | 6 months | 6 months | No |
a
Somatostatin analogs.
b
Cyclophosphamide, vincristine, and dacarbazine chemotherapy.
c
Temozolamide.
d
[123I]MIBG scintigraphy.
e
l-6-[18F]fluorodopa PET/CT.
f
[18F]Fludeoxyglucose PET/CT.
g
Somatostatin receptor scintigraphy.
h
[68Ga]Ga-DOTA-TOC PET/CT.
i
Complete response.
j
Partial response.
k
Stable disease.
l
Progressive disease.
++, very intense uptake; +, intense uptake; +/−, low or heterogeneous uptake; −, very low or absent uptake.